Perineural Invasion in Papillary Thyroid Cancer: A Rare Indicator of Aggressive Disease.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
12
07
2022
accepted:
12
02
2023
medline:
15
5
2023
pubmed:
11
3
2023
entrez:
10
3
2023
Statut:
ppublish
Résumé
Perineural invasion (PNI) is associated with aggressive tumor behavior, increased locoregional recurrence, and decreased survival in many carcinomas. However, the significance of PNI in papillary thyroid cancer (PTC) is incompletely characterized. Patients diagnosed with PTC and PNI from 2010-2020 at a single, academic center were identified and matched using a 1:2 scheme to patients without PNI based on gross extrathyroidal extension (ETE), nodal metastasis, positive margins, and tumor size (±4 cm). Mixed and fixed effects models were used to analyze the association of PNI with extranodal extension (ENE)-a surrogate marker of poor prognosis. In total, 78 patients were included (26 with PNI, 52 without PNI). Both groups had similar demographics and ultrasound characteristics preoperatively. Central compartment lymph node dissection was performed in most patients (71%, n = 55), and 31% (n = 24) underwent a lateral neck dissection. Patients with PNI had higher rates of lymphovascular invasion (50.0% vs. 25.0%, p = 0.027), microscopic ETE (80.8% vs. 44.0%, p = 0.002), and a larger burden [median 5 (interquartile range [IQR] 2-13) vs. 2 (1-5), p = 0.010] and size [median 1.2 cm (IQR 0.6-2.6) vs. 0.4 (0.2-1.4), p = 0.008] of nodal metastasis. Among patients with nodal metastasis, those with PNI had an almost fivefold increase in ENE [odds ratio [OR] 4.9 (95% confidence interval [CI] 1.5-16.5), p = 0.008] compared with those without PNI. More than a quarter (26%) of all patients had either persistent or recurrent disease over follow-up (IQR 16-54 months). PNI is a rare, pathologic finding that is associated with ENE in a matched cohort. Additional investigation into PNI as a prognostic feature in PTC is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Perineural invasion (PNI) is associated with aggressive tumor behavior, increased locoregional recurrence, and decreased survival in many carcinomas. However, the significance of PNI in papillary thyroid cancer (PTC) is incompletely characterized.
METHODS
METHODS
Patients diagnosed with PTC and PNI from 2010-2020 at a single, academic center were identified and matched using a 1:2 scheme to patients without PNI based on gross extrathyroidal extension (ETE), nodal metastasis, positive margins, and tumor size (±4 cm). Mixed and fixed effects models were used to analyze the association of PNI with extranodal extension (ENE)-a surrogate marker of poor prognosis.
RESULTS
RESULTS
In total, 78 patients were included (26 with PNI, 52 without PNI). Both groups had similar demographics and ultrasound characteristics preoperatively. Central compartment lymph node dissection was performed in most patients (71%, n = 55), and 31% (n = 24) underwent a lateral neck dissection. Patients with PNI had higher rates of lymphovascular invasion (50.0% vs. 25.0%, p = 0.027), microscopic ETE (80.8% vs. 44.0%, p = 0.002), and a larger burden [median 5 (interquartile range [IQR] 2-13) vs. 2 (1-5), p = 0.010] and size [median 1.2 cm (IQR 0.6-2.6) vs. 0.4 (0.2-1.4), p = 0.008] of nodal metastasis. Among patients with nodal metastasis, those with PNI had an almost fivefold increase in ENE [odds ratio [OR] 4.9 (95% confidence interval [CI] 1.5-16.5), p = 0.008] compared with those without PNI. More than a quarter (26%) of all patients had either persistent or recurrent disease over follow-up (IQR 16-54 months).
CONCLUSIONS
CONCLUSIONS
PNI is a rare, pathologic finding that is associated with ENE in a matched cohort. Additional investigation into PNI as a prognostic feature in PTC is warranted.
Identifiants
pubmed: 36897419
doi: 10.1245/s10434-023-13307-8
pii: 10.1245/s10434-023-13307-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3570-3577Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Rowe CW, Dill T, Griffin N, et al. Innervation of papillary thyroid cancer and its association with extra-thyroidal invasion. Sci Rep. 2020;10(1):1539. https://doi.org/10.1038/s41598-020-58425-5 .
doi: 10.1038/s41598-020-58425-5
pubmed: 32001748
pmcid: 6992619
Chen S-H, Zhang B-Y, Zhou B, Zhu C-Z, Sun L-Q, Feng Y-J. Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche. Am J Cancer Res. 2019;9(1):1–21.
pubmed: 30755808
pmcid: 6356921
Chatzistefanou I, Lubek J, Markou K, Ord RA. The role of perineural invasion in treatment decisions for oral cancer patients: a review of the literature. J Craniomaxillofac Surg. 2017;45(6):821–5. https://doi.org/10.1016/j.jcms.2017.02.022 .
doi: 10.1016/j.jcms.2017.02.022
pubmed: 28359633
Zhang L-J, Wu B, Zha Z-L, et al. Perineural invasion as an independent predictor of biochemical recurrence in prostate cancer following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. BMC Urol. 2018;18(1):5. https://doi.org/10.1186/s12894-018-0319-6 .
doi: 10.1186/s12894-018-0319-6
pubmed: 29390991
pmcid: 5796578
Cui L, Shi Y, Zhang GN. Perineural invasion as a prognostic factor for cervical cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2015;292(1):13–9. https://doi.org/10.1007/s00404-015-3627-z .
doi: 10.1007/s00404-015-3627-z
pubmed: 25637504
Deng J, You Q, Gao Y, et al. Prognostic value of perineural invasion in gastric cancer: a systematic review and meta-analysis. PLoS One. 2014;9(2):e88907. https://doi.org/10.1371/journal.pone.0088907 .
doi: 10.1371/journal.pone.0088907
pubmed: 24586437
pmcid: 3931634
Sezer A, Celik M, Yilmaz Bulbul B, et al. Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma. Bosn J Basic Med Sci. 2017;17(2):144–51. https://doi.org/10.17305/bjbms.2017.1924 .
doi: 10.17305/bjbms.2017.1924
pubmed: 28284178
pmcid: 5474108
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. https://doi.org/10.1089/thy.2015.0020 .
doi: 10.1089/thy.2015.0020
pubmed: 26462967
pmcid: 4739132
Clain JB, Scherl S, Dos Reis L, et al. Extrathyroidal extension predicts extranodal extension in patients with positive lymph nodes: an important association that may affect clinical management. Thyroid. 2014;24(6):951–7. https://doi.org/10.1089/thy.2013.0557 .
doi: 10.1089/thy.2013.0557
pubmed: 24443878
Zuniga S, Sanabria A. Prophylactic central neck dissection in stage N0 papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2009;135(11):1087–91. https://doi.org/10.1001/archoto.2009.163 .
doi: 10.1001/archoto.2009.163
pubmed: 19917919
Suh S, Pak K, Seok JW, Kim IJ. Prognostic value of extranodal extension in thyroid cancer: a meta-analysis. Yonsei Med J. 2016;57(6):1324–8. https://doi.org/10.3349/ymj.2016.57.6.1324 .
doi: 10.3349/ymj.2016.57.6.1324
pubmed: 27593858
pmcid: 5011262
Ricarte-Filho J, Ganly I, Rivera M, et al. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid. 2012;22(6):575–84. https://doi.org/10.1089/thy.2011.0431 .
doi: 10.1089/thy.2011.0431
pubmed: 22471242
pmcid: 5206680
Roh J-L, Park JW, Jeong J, et al. Extranodal extension of lymph node metastasis as a prognostic indicator of recurrence and survival in papillary thyroid carcinoma. J Surg Oncol. 2017;116(4):450–8. https://doi.org/10.1002/jso.24713 .
doi: 10.1002/jso.24713
pubmed: 28608492
Wu M-H, Shen WT, Gosnell J, Duh Q-Y. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer. Head Neck. 2015;37(9):1336–43. https://doi.org/10.1002/hed.23747 .
doi: 10.1002/hed.23747
pubmed: 24821456
Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metabil. 2005;90(10):5723–9. https://doi.org/10.1210/jc.2005-0285 .
doi: 10.1210/jc.2005-0285
Lango M, Flieder D, Arrangoiz R, et al. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid. 2013;23(9):1099–105. https://doi.org/10.1089/thy.2013.0027 .
doi: 10.1089/thy.2013.0027
pubmed: 23421588
pmcid: 3770240
Clain JB, Mehra S, Scherl S, et al. Intrathyroidal tumors presenting with extranodal extension: What are we missing? Endocr Pathol. 2014;25(4):385–9. https://doi.org/10.1007/s12022-014-9340-9 .
doi: 10.1007/s12022-014-9340-9
pubmed: 25325929
Sung T-Y, Cho JW, Lee Y-M, et al. Dynamic risk stratification in stage I papillary thyroid cancer patients younger than 45 years of age. Thyroid. 2017;27(11):1400–7. https://doi.org/10.1089/thy.2017.0199 .
doi: 10.1089/thy.2017.0199
pubmed: 28847226
Yamashita H, Noguchi S, Murakami N, et al. Extracapsular invasion of lymph node metastasis. Cancer. 1999;86(5):842–9.
doi: 10.1002/(SICI)1097-0142(19990901)86:5<842::AID-CNCR21>3.0.CO;2-X
pubmed: 10463984
Lee CW, Roh J-L, Gong G, et al. Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck. Ann Surg Oncol. 2015;22(1):117–24. https://doi.org/10.1245/s10434-014-3900-6 .
doi: 10.1245/s10434-014-3900-6
pubmed: 25034816
Wang LY, Palmer FL, Nixon IJ, et al. Lateral neck lymph node characteristics prognostic of outcome in patients with clinically evident n1b papillary thyroid cancer. Ann Surg Oncol. 2015;22(11):3530–6. https://doi.org/10.1245/s10434-015-4398-2 .
doi: 10.1245/s10434-015-4398-2
pubmed: 25665952
pmcid: 4977989
Ullmann TM, Liang H, Moore MD, Al-Jamed I, et al. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro. Surgery. 2020;167(1):56–63. https://doi.org/10.1016/j.surg.2019.04.076 .
doi: 10.1016/j.surg.2019.04.076
pubmed: 31585718
Park K, Tran H, Eng KW, et al. Performance characteristics of a targeted sequencing platform for simultaneous detection of single nucleotide variants, insertions/deletions, copy number alterations, and gene fusions in cancer genome. Arch Pathol Lab Med. 2020;144(12):1535–46. https://doi.org/10.5858/arpa.2019-0162-OA .
doi: 10.5858/arpa.2019-0162-OA
pubmed: 32045275
Deborde S, Omelchenko T, Lyubchik A, et al. Schwann cells induce cancer cell dispersion and invasion. J Clin Invest. 2016;126(4):1538–54. https://doi.org/10.1172/JCI82658 .
doi: 10.1172/JCI82658
pubmed: 26999607
pmcid: 4811155